Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting
Maryland, US 30 September 2022 - 03 October 2022
Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Nov 2022
byRoshini Claire Anthony
Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Nov 2022
Does salt intake truly affect outcomes in HF patients?
18 Oct 2022
byRoshini Claire Anthony
A small, single-centre study has suggested that increasing sodium intake does not affect weight or kidney function in patients hospitalized for acute heart failure (HF) who are undergoing aggressive diuretic therapy.